The precision medicine-based women’s health company CYduct Diagnostics Inc. (OTC:CYDX) is involved in the development of breast cancer diagnostic and risk assessment tools. On April 2, the company was in the news after it made an announcement about the positive results from the research on breast cancer biomarkers that it had concluded recently.
The pilot study that had deployed liquid biopsy samples had managed to meet its primary endpoint of measuring specific biomarker concentrations. The concentrations also demonstrated a strong correlation with regards to the prediction of breast health and a clinically meaningful improvement as opposed to the measurement of one biomarker.
However, CYduct Diagnostics noted that the overall data results were limited at the time of the announcement, but it had observed a secular positive trend. The company would conduct follow-up research in order to further refine the predictability and accuracy of its breast health assessment platform. The Chief Medical Officer of the company, Jill Dietz, spoke about the latest developments as well. She noted that the study had revealed that a particular combination of biomarkers could help in a transformative advance with regards to breast cancer assessment.
She went on to add that everyone at the company looked forward to the expansion of the breast health products into the prediction medicine risk assessment domain and eventually providing women with a revolutionary new testing option as soon as possible. In the news release, CYduct Diagnostics noted that the capability of detecting the early symptoms of breast cancer risk with specific biomarkers could help with early assessment significantly. On a theoretical level, this could help in the detection of small tumors that may not be visible through imaging, since it generally needs a tumor to be bigger than 5 mm in size for detection.
